Search research articles
Contact Us
Filters
Showing results (131-140 of 135) with videos related to
Page
of 14
Sort By:
You have reached the last page of results.
This site can display upto 135 results.
Clinical Immunology (Orlando, Fla.)
|
April 2, 2020
Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates
Sarah Hughes, Justin Gumas, Rebecca Lee, et al.
Shock (Augusta, Ga.)
|
February 21, 2018
Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock
Martijn van Griensven, Daniel Ricklin, Stephanie Denk, et al.
Nature Immunology
|
September 29, 2019
'Stealth' corporate innovation: an emerging threat for therapeutic drug development
Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Nature Immunology
|
October 13, 2019
Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development
Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 22, 2021
C1q binding to surface-bound IgG is stabilized by C1r<sub>2</sub>s<sub>2</sub> proteases
Seline A Zwarthoff, Kevin Widmer, Annemarie Kuipers, et al.
Page
of 14
Search research articles
Search
Showing results (131-140 of 135) with videos related to
Sort By:
Page
of 14
You have reached the last page of results.
This site can display upto 135 results.
Clinical Immunology (Orlando, Fla.)
|
April 2, 2020
Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates
Sarah Hughes, Justin Gumas, Rebecca Lee, et al.
Shock (Augusta, Ga.)
|
February 21, 2018
Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock
Martijn van Griensven, Daniel Ricklin, Stephanie Denk, et al.
Nature Immunology
|
September 29, 2019
'Stealth' corporate innovation: an emerging threat for therapeutic drug development
Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Nature Immunology
|
October 13, 2019
Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development
Dimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 22, 2021
C1q binding to surface-bound IgG is stabilized by C1r<sub>2</sub>s<sub>2</sub> proteases
Seline A Zwarthoff, Kevin Widmer, Annemarie Kuipers, et al.
Page
of 14